Table 1.
Currently ongoing clinical trials involving human anti-TIGIT mAbs.
| Agent | Trial sponsor | ClinicalTrials.gov identifier | Type of trial | Estimated enrollment | Tumor type | Combined therapy |
|---|---|---|---|---|---|---|
| BMS-986207 | Bristol-Myers Squibb | NCT02913313 | Phase 1/2 | 170 | Advanced solid tumors | Monotherapy or combined with nivolumab (anti-PD-1 mAb) |
| Multiple Myeloma Research Consortium | NCT04150965 | Phase 1/2 | 104 | Refractory multiple myeloma | Monotherapy or combined with pomalidomide and dexamethasone | |
| Compugen Ltd | NCT04570839 | Phase 1/2 | 100 | Advanced solid tumors | Combined with Nivo and COM701(inhibitor of poliovirus receptor) | |
| Genentech/Roche | NCT03563716 | Phase 2 | 135 | Locally advanced or metastatic Non-small cell lung cancer (NSCLC) | Combined with atezolizumab (anti-PD-L1 mAb) | |
| Tiragolumab (MTIG7192A; RG6058) | Roche | NCT04294810 | Phase 3 | 500 | Locally advanced or metastatic PD-L1-selected NSCLC |
Combined with atezolizumab |
| NCT04513925 | Phase 3 | 800 | NSCLC stage III | Combined with atezolizumab compared with Durvalumab | ||
| NCT04619797 | Phase 2 | 200 | Unresectable or metastatic NSCLC | Combined with atezolizumab and pemetrexed | ||
| NCT04256421 | Phase 3 | 400 | Untreated extensive-stage small cell lung cancer (SCLC) | Combined with atezolizumab and carboplatin and etoposide (CE) | ||
| NCT04308785 | Phase 2 | 363 | SCLC | Combined with atezolizumab VS atezolizumab | ||
| NCT03281369 | Phase 1b/2 | 410 | Esophageal cancer | Combined with atezolizumab VS atezolizumab and chemotheraoy | ||
| NCT04540211 | Phase 3 | 450 | Unresectable esophageal cancer | Combined with atezolizumab +paclitaxel and cisplatin (PC) VS placebo+PC | ||
| NCT04543617 | Phase 3 | 750 | Unresectable esophageal squamous cell carcinoma | Combined with atezolizumab VS atezolizumab | ||
| NCT04524871 | Phase 1/2 | 100 | Advanced liver cancers | Combined with Atezolizumab + Bevacizumab | ||
| NCT04584112 | Phase 1 | 80 | Triple-negative breast cancer | Combined with atezolizumab + chemotherapy | ||
| NCT04045028 | Phase 1 | 52 | Refractory multiple myeloma | Monotherapy or combined with daratumumab or rituximab | ||
| NCT02794571 | Phase 1 | 540 | Locally advanced or metastatic tumors | Monotherapy or in combined with atezolizumab and/or other anti-cancer therapies | ||
| NCT04300647 | Phase 2 | 220 | Cervical cancer (PD-L1-positive) | Combined with atezolizumab | ||
| NCT03281369 | Phase 1/2 | 410 | Gastric and esophageal cancer | Combined with atezolizumab with/without cisplatin+5FU | ||
| NCT03193190 | Phase 1/2 | 290 | Metastatic pancreatic ductal Adenocarcinoma | Combined with atezolizumab +chemotherapy | ||
| NCT03869190 | Phase 1/2 | 385 | Locally advanced or metastatic urothelial carcinoma | Combined with atezolizumab | ||
| Tiragolumab (MTIG7192A; RG6058) | Roche | NCT04665843 | Phase 2 | 120 | PD-L1-positive squamous cell carcinoma of the head and neck | Combined with atezolizumab |
| NCT03708224 | Phase 2 | 55 | Squamous cell carcinoma of the head and neck | Combined with atezolizumab VS atezolizumab | ||
| MK-7684 | Merck | NCT02964013 | Phase 1 | 492 | Advanced solid tumors | Monotherapy or combined with pembrolizumab (anti-PD-1 mAb) |
| NCT04305041 | Phase 1/2 | 200 | Melanoma | Combined with pembrolizumab VS pembrolizumab | ||
| NCT04305054 | Phase 1/2 | 135 | Melanoma | Combined with pembrolizumab VS pembrolizumab | ||
| NCT04738487 | Phase 3 | 598 | PD-L1 positive metastatic NSCLC | Combined with pembrolizumab VS pembrolizumab | ||
| NCT04725188 | Phase 2 | 240 | Metastatic NSCLC | Combined with pembrolizumab +Docetaxel VS Docetaxel | ||
| NCT04165070 | Phase 2 | 90 | Advanced NSCLC | Combined with pembrolizumab + Carboplatin + Paclitaxel | ||
| NCT02861573 | Phase 1 | 1000 | Metastatic castrate resistant prostate cancer | Combined with pembrolizumab | ||
| NCT04303169 | Phase 1/2 | 65 | Stage III melanoma | Combined with pembrolizumab VS pembrolizumab | ||
| AB154 | Arcus Biosciences | NCT03628677 | Phase 1 | 66 | Advanced solid tumors | Monotherapy or combined with AB122 (anti-PD-1 mAb) |
| NCT04262856 | Phase 2 | 150 | NSCLC | Combined with AB122 or AB122 and AB928 (dual adenosine receptor antagonist) | ||
| NCT04656535 | Phase 1 | 46 | Recurrent glioblastoma | Combined with AB122 | ||
| NCT04736173 | Phase 3 | 625 | PD-L1 positive metastatic NSCLC | Combined with AB122 VS AB122 | ||
| COM902 | Compugen | NCT04354246 | Phase 1 | 45 | Advanced malignant tumors | Monotherapy |
| IBI939 | Innovent Biologics | NCT04353830 | Phase 1 | 270 | Advanced malignant tumors | Monotherapy or combined with sintilimab (anti-PD-1 mAb) |
| NCT04672356 | Phase 1 | 20 | Advanced lung cancer | Combined with sintilimab | ||
| NCT04672369 | Phase 1 | 42 | Advanced NSCLC | Combined with sintilimab VS sintilimab | ||
| BGB-A1217 | BeiGene | NCT04047862 | Phase 1 | 39 | Advanced solid tumors | Monotherapy or combined with tislelizumab (anti-PD-1 mAb) |
| NCT04732494 | Phase 2 | 280 | Recurrent or metastatic Esophageal squamous cell carcinoma | Combined with tislelizumab VS tislelizumab +placebo | ||
| NCT04746924 | Phase 3 | 605 | Locally advanced or metastatic NSCLC | Combined with tislelizumab VS pembrolizumab+placebo | ||
| NCT04693234 | Phase 2 | 167 | Metastatic cervical cancer | Combined with tislelizumab VS tislelizumab | ||
| ASP8374 | Astellas Pharma | NCT03260322 | Phase 1 | 169 | Advanced solid tumors | Monotherapy or combined with pembrolizumab (anti-PD-1 mAb) |
| NCT03945253 | Phase 1 | 6 | Advanced solid tumors | Monotherapy | ||
| M6223 | EMD Serono | NCT04457778 | Phase 1 | 35 | Advanced solid tumors | Monotherapy or combined with Bintrafusp alfa |